TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06191991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: 0.9 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: 0.9 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg
Study: NCT05600556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Review imaging on standard computer screen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Technology Intervention
Description: Review virtual reality images

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT05952674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: Best Medical Treatment for resistant depression.
Study: NCT06550284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The intervention will be physical therapy standard care.
Study: NCT04078997

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.

Intervention type: OTHER
Intervention: nasopharyngeal swab
Description: A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
Study: NCT04880603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restrata Graft
Description: Restrata will be meshed in a 1:2 fashion to allow for egress of serous fluid and minimize risk of fluid collection. Restrata will be applied to the entire wound bed not amenable to primary closure and will be underlaid beneath the surrounding skin edges. A split-thickness skin graft is harvested from patient's thigh at 15:1000 inches and placed on top of the Restrata to cover the entire wound bed. The graft is sutured in place using suture choice of surgeon's preference.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Skin Graft
Description: Standard of Care Skin Graft
Study: NCT05222698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facial reanimation surgery by free muscle trasfer.
Description: Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Facial reanimation surgery by free muscle trasfer.
Description: Muscle flap harvesting from the back or from the thigh to be insetted to the paralyzed side of the face with microvascular anastomosis of the muscle pedicle to facial artery and vein.
Study: NCT05321732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP16001
Description: DWP16001 A mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP202010
Description: DWP202010 B mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP202010
Description: DWP202010 B mg
Study: NCT05970757

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Extended MRI
Description: Extension of the brain tumor MRI-protocol
Study: NCT06157723

Intervention type: OTHER
Intervention: None (Observational study)
Description: Data related to the knee osteoarthritis will be extracted from patients' medical records:~The sociodemographic and clinical participants' characteristics: age, weight, height, duration of the condition, and occupational activity.~The healthcare costs: the number of visits in primary and specialized care, diagnostic tests, surgical interventions, and emergencies at both health centers and hospitals, physical rehabilitation and number of sessions.~Charlson Comorbidity Index (CCI). Pharmacotherapy (type of drug and dose). Work absences (temporary and permanent).
Study: NCT04763915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies (Survey)
Description: Administer surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies (Survey)
Description: Administer surveys

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Correlative Studies (Survey)
Description: Administer surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies (Survey)
Description: Administer surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies (Interview)
Description: In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention
Study: NCT05414344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Brief Intervention
Description: Immediately following completion of the baseline assessment, participants will be texted a link to a secure website which contains the participant's personalized feedback. Personalized feedback is automatically presented via a programming algorithm that is based on the participants baseline survey responses. The personalized feedback component will include a personalized substance use profile, information on peer norms, prior substance-related consequences experienced by the participant, practical costs (e.g., money spent on substances, fees for a DUI), and standard protective behavioral strategies to limit substance-related risk.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed and Peer-Supported Brief Intervention
Description: In addition to the components of the standard brief intervention, the TIPS-BI will include personalized feedback about participants use of substances to cope. Additionally, participants will be provided with psychoeducation about the link between substance use, trauma, and coping motives, and information highlighting the iatrogenic effects that substance use has on negative emotions. Participants will also be given a series of evidence-based alternative coping strategies for managing trauma-related distress such as anxiety, depression, and PTSD. Participants will be asked to set goals related to utilization of these alternative coping strategies. Participants will then be informed that a trained peer who is part of the research team will follow up with them via text message at the monthly time points to review adherence to their goals and offer support.
Study: NCT04584346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquigen MCT oil
Description: MCT oil is a nutritional supplement. The Ketogenic diet restricted carbohydrates to reach 80/5-10/10-15 (lipid:carb:protein daily energy) values

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard American Diet
Description: Standard diet with macronutrient composition lipid 35%, protein 10-15%, carbohydrate 50-55%
Study: NCT05414344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment only
Description: Following the baseline survey, participants in the assessment only group will be texted again 3 and 6 months later to complete follow up assessments. Following the end of the 6-month follow-up, participants will be offered an opportunity to complete the TIPS-BI without peer coach follow-up.
Study: NCT05349552

Intervention type: RADIATION
Intervention: stereotactic body radiation therapy
Description: The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
Study: NCT05137457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivering Online ZZZ's with Empirical support (DOZE) app
Description: The DOZE app is a unique digital CBTi intervention that can be used on any mobile phone, tablet or computer, using the iPhone Operating System (iOS) or Android software. It is an innovative program that consists of an integrated smart phone app and web self-management system (DOZE) to help adolescents and young adults to sleep better. It allows data capture through entries in a sleep diary and calculation of specific clinical indices. The acquisition of baseline sleep health data over a two-week period is then used to provide personalized targets and tailored therapeutic interventions during the treatment phase. The app also includes a self-monitoring tool that fosters goal setting and provides feedback on sleep and goal attainment. DOZE allows for real time assessment of sleep related behaviors and customized reports and graphs from the young adults' data. The app provides reminders about specific goals and positive feedback (increasing scores) for each step towards a goal.
Study: NCT05349552

Intervention type: RADIATION
Intervention: stereotactic body radiation therapy
Description: The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.

Intervention type: RADIATION
Intervention: stereotactic body radiation therapy
Description: The patients were treated with high-dose and low fractionated radiotherapy, using modern precision radiotherapy technology.
Study: NCT05137457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep diary
Description: The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep diary
Description: The control group will receive the control version of the DOZE app where the patients will be able to access the sleep diary only, without the CBTi intervention. Participants will simply use the app to input entries into their sleep diary as an attention control over a 10-week period.
Study: NCT05045742

Intervention type: OTHER
Intervention: Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2
Description: We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2

Intervention type: OTHER
Intervention: Traditional vital sign alarms versus the BioVitals Index vs the National Early Warning Score 2
Description: We will retrospectively compare the alarms produced from traditional vital sign alarms (thresholds set by clinicians) versus the BioVitals Index vs the National Early Warning Score 2
Study: NCT04763915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies (Interview)
Description: In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Correlative Studies (Interview)
Description: In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GeneSHARE
Description: Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LivingLabReport
Description: Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care & Adaptive Intervention
Description: Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to Education Materials
Description: Receive access to VUS educational materials
Study: NCT06053073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical rippening at home
Description: The experimental arm of the study will undergo cervical rippening at home between 6 and 8 hours and then will come back to the hospital to continue with the labor induction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical rippening in the hospital
Description: The active comparator arm of the study will undergo cervical rippening in the hospital between 6 and 8 hours and then will remain there to continue with the labor induction
Study: NCT06432374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WET
Description: The five weekly WET sessions were delivered online via Canvas. Five session modules were created, each containing writing instructions for the respective session and an assignment feature for participants to upload their narratives. All sessions included 30 minutes of writing. Following instructions, participants wrote about a specific work-related trauma event in detail and described the emotions and thoughts experienced during the event. While all sessions were self-paced, participants were advised to complete each subsequent session within one week. Participants had the option to self-administer sessions or participate in Zoom office hours for live writing sessions with a facilitator who had completed WET training providing the writing instructions.
Study: NCT05332873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivet Shunt
Description: The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
Study: NCT06216704

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance relaxometry
Description: Spin-lattice relaxation (T1) relaxometry acquisition consisting of fast spin echo (FSE) acquisitions through the knee. T1 maps from the T1 relaxometry images will be generated using a two-parameter-fit iterative algorithm developed in-house using IDL software (Harris Geospatial Solutions, Melbourne, FL, USA). Mean T1 values for each region will be recorded. The anatomical locations of these regions will be consistent in size for all subjects and location. The locations chosen for the primary endpoints are ones that are known to be rich in red and yellow marrow, respectively.
Study: NCT06416956

Intervention type: DRUG
Intervention: Caffeine
Description: We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
Study: NCT06551415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate 150mg
Description: 100 CVT patients will receive dabigatran 150mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: 100 CVT patients will receive apixaban 5mg Bid for 6 months. We will assess the Proportion of subjects who have partial or complete venous recanalization by Day 180 the rate of drug hemorrhagic complications using the PLATO bleeding definition, and the rates of patients who achieved a favorable outcome with (mRS = 0-2) after one week and after 180 days in a face-to-face interview in the outpatient clinic, Proportion of subjects with recurrent venous thromboembolism (any thrombosis at a new site, including cerebral venous thrombosis in a separate location from the index event) at Day 180 or the end of anticoagulation, whichever is sooner, rates of a composite of pulmonary embolism, DVT, myocardial infarction, and death due to vascular events after 180 days of follow-up, the MoCA, HIT-6 by 180 days, the rate of treatment-related adverse effects assessed by a follow-up questionnaire.
Study: NCT05738278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HR-informed change in routine
Description: The intervention is given for a situation occuring at least ten times and accompanied by an increase in HR at least 80% of the time, during the two-week registration period. Change in care (intervention) is introduced from week 3.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed HR-informed specific change in routine
Description: The intervention is given for a situation occuring at least twenty times and accompanied by an increase in HR at least 80% of the time, during the four-week registration period. Change in care (intervention) is introduced from week 5.~The intervention is in one of four forms:~1. changes in physiotherapy, e.g., less rigorous movement in the identified painful stretch,~2. preparations for putting on corrective cast to stabilize joint and/or stretch spastic muscles,~3. change in procedures for transportation/lifting, e.g., new technique or adaptations made to equipment, or~4. revised personal hygiene procedure.
Study: NCT05138991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiogram Recording
Description: Undergo assessment via echo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary Studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Cardiac Magnetic Resonance Imaging
Description: Undergo assessment via CMR

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wireless Synchronized Cardiac Function Monitoring Device
Description: SphygmoCor® Xcel Oscar 2™ Ambulatory Blood Pressure Monitor
Study: NCT06469203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9% Inj
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Women undergoing dilation and curettage, who meet the eligibility criteria for the study, will be divided into two groups. They will receive the assigned medication at the beginning of the procedure, after cervical dilation but before using suction curettage.~Group 1: Participants will receive 100 ml of saline alone. Group 2: Participants will receive an intravenous infusion of 8 units of oxytocin diluted in 100 ml of saline.
Study: NCT06440993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 1,000 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 25 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, 1,500 mg IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ID-RFA
Description: endoscopic intraductal RFA